The expression of CD73 on pathological B-cells is associated with shorter overall survival of patients with CLL

Kicova, M; Michalová, Zuzana; Čoma, Matúš; Gabzdilová, Juliana; Dedinská, Kinga; Guman, Tomáš; Bernatova, S; Hajikova, M; Giertlová, Mária; Veselinyová, Dominika; Šarišský, Marek

doi:10.4149/neo_2020_190826n822

Cited by 8 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Advia 2120's comprehensive blood image and haematological analyzer employ laser light scatter technology to compute the blood count and differential. For each cell, the low angle (2-3) and high angle (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15) scatters are converted into volume and inner structure values (for haemoglobin, leukocytes' nuclei, and platelets' granules) [6] . Flow cytometric analysis of CD73 and CD19 expression on Becton Dickinson FACSC alibur.…”

Section: Methodsmentioning

confidence: 99%

Study of CD73 Expression on B Lymphocytes in patients with chronic lymphocytic leukemia

Zohery,

Gawaly,

Mohamed

et al. 2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

Background: A subgroup of T and B cells express the extracellular enzyme cluster of differentiation (CD73), which hydrolyzes adenosine monophosphate to adenosine. This work aimed to evaluate CD73 expression and its correlation with other disease characteristics in leukemia of chronic lymphocytic type (CLL) patients. Methods: This cross-sectional research was done on 30 CLL cases diagnosed by laboratory investigations or presented with fatigue and fever with or without lymphadenopathy and organomegaly, and a healthy control group of 30 age-and sex-matched individuals. All patients had subjected to estimation of β2 microglobulin, flowcytometric detection of CD73 and CD19 in peripheral blood. Results: In neither group did CD19/CD73 expression and haemoglobin significantly correlate. microglobulin in control group. While, the CD19/CD73 expression had positive significant correlation with B2 macroglobulin in CLL group. In the CLL group, haemoglobin level, platelet count, and CD19/CD73 expression were all noticeably reduced. B2 microglobulin, however, was noticeably greater in the CLL group. CD19/CD73 expression can diagnose CLL with high accuracy (100%) at cutoff 16.8, sensitivity, specificity, PPV and NPV were 100%. Conclusions: When compared to controls, most CLL patients have less expression of CD19CD73, making it useful in standard diagnostic immunophenotyping workup. At the cut-off point of 16.8, CD19/CD73 expression has a high sensitivity (100%) for the diagnosis of CLL.

show abstract

Section: Methodsmentioning

confidence: 99%

Study of CD73 Expression on B Lymphocytes in patients with chronic lymphocytic leukemia

Zohery,

Gawaly,

Mohamed

et al. 2023

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

show abstract

“…CD73 expression may also be related to the prognosis of CLL. M. Kicova et al showed that high CD73 expression is related to the significant shortening of the overall survival time of CLL patients (75). This was the first time that researchers have directly proven the effect of CD73 expression on the survival of patients with CLL.…”

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 96%

“…This was the first time that researchers have directly proven the effect of CD73 expression on the survival of patients with CLL. In addition, CD73 expression has been found on B cells in CLL patients, and Serra et al found that high CD73 expression is associated with more aggressive clinical behavior, which is characterized by large CLL clones and poor prognosis (75,76). Therefore, further research is needed to determine the effect of CD73 expression in patients with progressive disease.…”

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 99%

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy

Jiang

Wu²,

Xiao³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Hematological malignancy develops and applies various mechanisms to induce immune escape, in part through an immunosuppressive microenvironment. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment (TME). Adenosine signaling through the A2A receptor expressed on immune cells, such as T cells, potently dampens immune responses. Extracellular adenosine generated by ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and ecto-5’-nucleotidase (CD73) molecules is a newly recognized ‘immune checkpoint mediator’ and leads to the identification of immunosuppressive adenosine as an essential regulator in hematological malignancies. In this Review, we provide an overview of the detailed distribution and function of CD39 and CD73 ectoenzymes in the TME and the effects of CD39 and CD73 inhibition on preclinical hematological malignancy data, which provides insights into the potential clinical applications for immunotherapy.

show abstract

“…Further, these CD73 + NK cells also express other inhibitory checkpoints and they can suppress CD4 + T-cell proliferation and IFN-γ production, thus promoting tumor growth. Notably, CD73 and CD39 are not only expressed on solid tumors but also in hematological malignancies [ 69 , 76 , 77 , 78 , 79 ]. More interestingly, it has been reported that the expression of CD39 on MSC increases significantly after co-culture with activated lymphocytes [ 80 ].…”

Section: Current Advanced Therapy In Hematological Malignanciesmentioning

confidence: 99%

Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies

Giuliani

Poggi

2020

Cells

View full text Add to dashboard Cite

Natural killer (NK) cells represent one of the first lines of defense against malignant cells. NK cell activation and recognition are regulated by a balance between activating and inhibitory receptors, whose specific ligands can be upregulated on tumor cells surface and tumor microenvironment (TME). Hematological malignancies set up an extensive network of suppressive factors with the purpose to induce NK cell dysfunction and impaired immune-surveillance ability. Over the years, several strategies have been developed to enhance NK cells-mediated anti-tumor killing, while other approaches have arisen to restore the NK cell recognition impaired by tumor cells and other cellular components of the TME. In this review, we summarize and discuss the strategies applied in hematological malignancies to block the immune check-points and trigger NK cells anti-tumor effects through engineered chimeric antigen receptors.

show abstract

The expression of CD73 on pathological B-cells is associated with shorter overall survival of patients with CLL

Cited by 8 publications

References 5 publications

Study of CD73 Expression on B Lymphocytes in patients with chronic lymphocytic leukemia

Study of CD73 Expression on B Lymphocytes in patients with chronic lymphocytic leukemia

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy

Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies

Contact Info

Product

Resources

About